AbbVie Reconsiders Shire Offer
AbbVie sends Shire notice that it is reconsidering its offer recommendation.
Breaking News: AbbVie/Shire Deal Is Officially Off
UPDATE (Oct. 16, 2014)...Reuters is reporting that AbbVie's Board of Directors has recommended that shareholders vote against the proposed takeover of Shire. If AbbVie's shareholders do decide to withdraw the offer, Shire may receive a $1.64-billion break fee.
...................
Reuters is reporting that AbbVie is reconsidering its acquisition of Shire as a result of US tax law proposals that would limit the ability of American companies to shift their tax bases out of the United States. AbbVie’s board will meet to discuss the impact of the US Department of Treasury changes to tax regulations on October 20. AbbVie announced its interest in Shire in July.
Shire confirmed receipt of AbbVie’s notice of its consideration to either withdraw or modify its offer recommendation in a statement on the company’s website. In the Shire statement, the Board of Shire expresses its belief that AbbVie should proceed with the recommended offer.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
